Contact Us
Drug Search Results
More Filters [+]

CKD-397

Alternative Names: ckd-397, ckd397, ckd 397
Latest Update: 2017-08-09
Latest Update Note: Clinical Trial Update

Product Description

Chong Kun Dang was developing ckd-397, an oral ADRA1A agonist,PDE5 Inhibitor, for the treatment of Benign Prostatic Hypertrophy (BPH) (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02615782)

Mechanisms of Action: ADRA1A agonist,PDE5 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Chong Kun Dang
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CKD-397

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Prostatic Hyperplasia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
150FDI15031

P1

Completed

Prostatic Hyperplasia

2016-04-01

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions